Caladrius Biosciences (CLBS) Reports Q4 Loss Per Share of 59c, Affirms FY16 Rev. Guidance

Caladrius Biosciences (NASDAQ: CLBS) reported Q4 EPS of ($0.59), $0.31 worse than the analyst estimate of ($0.28). Revenue for the quarter came in at $7.6 million versus the consensus estimate of $7.67 million.

For 2016, Caladrius affirms expectations for total revenues to exceed $30 million, representing an increase of greater than 30% compared with 2015. In order to support this projected growth, Caladrius expects to spend $6 million in capital improvements to increase PCT’s Allendale, N.J. clean room capacity by 60%, and expects to complete the build-out in 2016. Caladrius also estimates that it will incur restructuring charges of approximately $1.0 million in connection with one-time employee termination costs, including severance and other benefits, in the first quarter of 2016. The Company estimates that the previously announced staff reductions will result in more than $4 million in annualized compensation-related savings, and anticipates significant cost savings associated with terminating the CLBS20 study, which had been estimated to cost $35 million through its completion. In addition, with a narrowed focus on research and development initiatives, as well as a re-sizing of the Company’s general and administrative infrastructure, Caladrius expects to lower R&D, SG&A and overall cash burn in 2016 compared with 2015.

For earnings history and earnings-related data on Caladrius Biosciences (CLBS) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c